Department of Neuroradiology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J Neurooncol. 2018 Sep;139(2):431-440. doi: 10.1007/s11060-018-2881-x. Epub 2018 Apr 27.
The purpose of this study is to map spatial metabolite differences across three molecular subgroups of glial tumors, defined by the IDH1/2 mutation and 1p19q-co-deletion, using magnetic resonance spectroscopy. This work reports a new MR spectroscopy based classification algorithm by applying a radiomics analytics pipeline.
65 patients received anatomical and chemical shift imaging (5 × 5 × 20 mm voxel size). Tumor regions were segmented and registered to corresponding spectroscopic voxels. Spectroscopic features were computed (n = 860) in a radiomic approach and selected by a classification algorithm. Finally, a random forest machine-learning model was trained to predict the molecular subtypes.
A cluster analysis identified three robust spectroscopic clusters based on the mean silhouette widths. Molecular subgroups were significantly associated with the computed spectroscopic clusters (Fisher's Exact test p < 0.01). A machine-learning model was trained and validated by public available MRS data (n = 19). The analysis showed an accuracy rate in the Random Forest model by 93.8%.
MR spectroscopy is a robust tool for predicting the molecular subtype in gliomas and adds important diagnostic information to the preoperative diagnostic work-up of glial tumor patients. MR-spectroscopy could improve radiological diagnostics in the future and potentially influence clinical and surgical decisions to improve individual tumor treatment.
本研究旨在利用磁共振波谱(MRS)对 IDH1/2 突变和 1p19q 共缺失定义的三种神经胶质瘤分子亚组的空间代谢物差异进行定位。本研究报告了一种新的基于 MRS 的分类算法,该算法应用了放射组学分析流程。
65 名患者接受了解剖和化学位移成像(5×5×20mm 体素大小)。对肿瘤区域进行分割,并注册到相应的波谱体素。在放射组学方法中计算了光谱特征(n=860),并通过分类算法进行选择。最后,随机森林机器学习模型被用来预测分子亚型。
聚类分析根据平均轮廓宽度确定了三个稳健的光谱聚类。分子亚组与计算出的光谱聚类显著相关(Fisher 精确检验 p<0.01)。通过公共可用的 MRS 数据(n=19)训练和验证了机器学习模型。分析表明,随机森林模型的准确率为 93.8%。
MRS 是预测神经胶质瘤分子亚型的有力工具,为神经胶质瘤患者的术前诊断提供了重要的诊断信息。MRS 有可能在未来改善放射学诊断,并有可能影响临床和手术决策,以改善个体肿瘤的治疗效果。